76.22
price up icon1.64%   1.23
pre-market  Pre-mercato:  78.32   2.10   +2.76%
loading
Precedente Chiudi:
$74.99
Aprire:
$75.46
Volume 24 ore:
3.59M
Relative Volume:
0.80
Capitalizzazione di mercato:
$44.71B
Reddito:
$5.54B
Utile/perdita netta:
$4.18B
Rapporto P/E:
10.89
EPS:
7
Flusso di cassa netto:
$623.10M
1 W Prestazione:
-2.07%
1M Prestazione:
+0.24%
6M Prestazione:
+5.76%
1 anno Prestazione:
-13.37%
Intervallo 1D:
Value
$75.28
$76.47
Intervallo di 1 settimana:
Value
$74.20
$77.77
Portata 52W:
Value
$58.93
$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name
Nome
Edwards Lifesciences Corp
Name
Telefono
(949) 250-2500
Name
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Name
Dipendente
15,800
Name
Cinguettio
@edwardslifesci
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
EW's Discussions on Twitter

Confronta EW con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Medical Devices icon
EW
Edwards Lifesciences Corp
76.22 45.66B 5.54B 4.18B 623.10M 7.00
Medical Devices icon
ABT
Abbott Laboratories
132.94 235.23B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
106.17 157.62B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
383.78 148.87B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
81.18 110.72B 33.54B 4.66B 5.19B 3.62

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-24 Aggiornamento Piper Sandler Neutral → Overweight
2025-01-30 Aggiornamento Stifel Hold → Buy
2025-01-16 Downgrade Wolfe Research Peer Perform → Underperform
2024-12-16 Aggiornamento BofA Securities Neutral → Buy
2024-10-11 Ripresa Morgan Stanley Equal-Weight
2024-09-18 Downgrade Jefferies Buy → Hold
2024-07-31 Aggiornamento Daiwa Securities Neutral → Outperform
2024-07-29 Aggiornamento Wolfe Research Underperform → Peer Perform
2024-07-25 Downgrade BofA Securities Buy → Neutral
2024-07-25 Downgrade JP Morgan Overweight → Neutral
2024-07-25 Downgrade Robert W. Baird Outperform → Neutral
2024-07-25 Downgrade TD Cowen Buy → Hold
2024-07-25 Downgrade Truist Buy → Hold
2024-05-30 Iniziato Goldman Buy
2024-05-22 Aggiornamento Citigroup Neutral → Buy
2024-05-14 Aggiornamento Deutsche Bank Hold → Buy
2024-03-07 Aggiornamento BofA Securities Neutral → Buy
2024-02-02 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-01-04 Downgrade Evercore ISI Outperform → In-line
2023-12-11 Downgrade Citigroup Buy → Neutral
2023-11-28 Downgrade Wolfe Research Peer Perform → Underperform
2023-09-26 Aggiornamento Oppenheimer Perform → Outperform
2023-07-19 Iniziato Robert W. Baird Outperform
2023-05-30 Ripresa Morgan Stanley Overweight
2023-03-29 Iniziato UBS Neutral
2023-03-08 Downgrade Wells Fargo Overweight → Equal Weight
2023-02-06 Downgrade Raymond James Outperform → Mkt Perform
2023-01-31 Downgrade Bernstein Outperform → Underperform
2023-01-30 Downgrade Piper Sandler Overweight → Neutral
2022-12-06 Downgrade Stifel Buy → Hold
2022-10-28 Downgrade Oppenheimer Outperform → Perform
2022-10-26 Iniziato Mizuho Buy
2022-10-18 Iniziato Barclays Overweight
2022-10-12 Iniziato Jefferies Buy
2022-07-29 Downgrade Canaccord Genuity Buy → Hold
2022-04-13 Iniziato Truist Buy
2022-04-06 Iniziato Wolfe Research Outperform
2022-03-16 Aggiornamento Bernstein Mkt Perform → Outperform
2022-03-02 Ripresa BofA Securities Neutral
2022-02-02 Aggiornamento UBS Neutral → Buy
2022-01-27 Reiterato Citigroup Buy
2022-01-27 Reiterato Evercore ISI Outperform
2022-01-27 Reiterato Raymond James Outperform
2022-01-27 Reiterato Stifel Buy
2022-01-27 Reiterato UBS Neutral
2021-12-17 Aggiornamento JP Morgan Neutral → Overweight
2021-12-15 Aggiornamento Citigroup Neutral → Buy
2021-12-10 Iniziato RBC Capital Mkts Outperform
2021-12-06 Aggiornamento Wells Fargo Equal Weight → Overweight
2021-07-30 Reiterato Canaccord Genuity Buy
2021-07-30 Reiterato Deutsche Bank Hold
2021-07-30 Reiterato Jefferies Buy
2021-07-30 Reiterato Morgan Stanley Overweight
2021-07-30 Reiterato Oppenheimer Outperform
2021-07-30 Reiterato Stifel Buy
2021-07-30 Reiterato UBS Neutral
2021-07-30 Reiterato Wells Fargo Equal Weight
2021-05-25 Iniziato Barclays Overweight
2021-04-15 Iniziato Atlantic Equities Neutral
2021-04-05 Aggiornamento Evercore ISI In-line → Outperform
2020-12-16 Downgrade Citigroup Buy → Neutral
2020-12-11 Reiterato Canaccord Genuity Buy
2020-09-11 Iniziato Wolfe Research Underperform
2020-04-28 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-03-05 Iniziato Citigroup Buy
2020-02-13 Iniziato Goldman Neutral
2020-02-06 Ripresa BTIG Research Neutral
2020-01-10 Iniziato Oppenheimer Outperform
2020-01-02 Downgrade Evercore ISI Outperform → In-line
2019-10-24 Reiterato Canaccord Genuity Buy
2019-09-23 Iniziato Piper Jaffray Overweight
2019-07-24 Reiterato BofA/Merrill Buy
2019-03-18 Reiterato Canaccord Genuity Buy
2019-01-18 Aggiornamento BofA/Merrill Neutral → Buy
2019-01-03 Iniziato Deutsche Bank Hold
2018-11-28 Iniziato UBS Neutral
2018-10-16 Iniziato Barclays Underweight
2018-10-02 Downgrade BofA/Merrill Buy → Neutral
2018-10-02 Downgrade Guggenheim Buy → Neutral
Mostra tutto

Edwards Lifesciences Corp Borsa (EW) Ultime notizie

pulisher
08:15 AM

Edwards Lifesciences stock rises following competitor’s exit - Investing.com

08:15 AM
pulisher
May 24, 2025

Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com

May 24, 2025
pulisher
May 23, 2025

Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech

May 23, 2025
pulisher
May 23, 2025

Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance

May 23, 2025
pulisher
May 22, 2025

Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice

May 22, 2025
pulisher
May 22, 2025

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com

May 22, 2025
pulisher
May 21, 2025

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing

May 18, 2025
pulisher
May 16, 2025

Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post

May 15, 2025
pulisher
May 14, 2025

Edwards Lifesciences Completes Sale of Critical Care - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq

May 14, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com

May 13, 2025
pulisher
May 12, 2025

FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal

May 12, 2025
pulisher
May 09, 2025

Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

May 08, 2025
pulisher
May 06, 2025

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

May 06, 2025
pulisher
May 02, 2025

Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025
pulisher
May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025
pulisher
Apr 28, 2025

Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq

Apr 28, 2025
pulisher
Apr 26, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com

Apr 24, 2025

Edwards Lifesciences Corp Azioni (EW) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$85.33
price up icon 0.97%
$71.01
price up icon 2.67%
medical_devices SNN
$28.92
price up icon 1.01%
medical_devices STE
$246.20
price up icon 1.32%
$326.64
price up icon 1.64%
Capitalizzazione:     |  Volume (24 ore):